Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models.

Elliott M, Favre-Guilmard C, Liu SM, Maignel J, Masuyer G, Beard M, Boone C, Carré D, Kalinichev M, Lezmi S, Mir I, Nicoleau C, Palan S, Perier C, Raban E, Zhang S, Dong M, Stenmark P, Krupp J.

Sci Adv. 2019 Jan 16;5(1):eaau7196. doi: 10.1126/sciadv.aau7196. eCollection 2019 Jan.

2.

A comparison of biological activity of commercially available purified native botulinum neurotoxin serotypes A1 to F1 in vitro, ex vivo, and in vivo.

Donald S, Elliott M, Gray B, Hornby F, Lewandowska A, Marlin S, Favre-Guilmard C, Périer C, Cornet S, Kalinichev M, Krupp J, Fonfria E.

Pharmacol Res Perspect. 2018 Nov 22;6(6):e00446. doi: 10.1002/prp2.446. eCollection 2018 Dec.

3.

The Expanding Therapeutic Utility of Botulinum Neurotoxins.

Fonfria E, Maignel J, Lezmi S, Martin V, Splevins A, Shubber S, Kalinichev M, Foster K, Picaut P, Krupp J.

Toxins (Basel). 2018 May 18;10(5). pii: E208. doi: 10.3390/toxins10050208. Review.

4.

ADX71943 and ADX71441, novel positive allosteric modulators of the GABAB receptor with distinct central/peripheral profiles, show efficacy in the monosodium iodoacetate model of chronic osteoarthritis pain in the rat.

Kalinichev M, Donovan-Rodriguez T, Girard F, Haddouk H, Royer-Urios I, Schneider M, Bate ST, Marker C, Pomonis JD, Poli S.

Eur J Pharmacol. 2017 Jan 15;795:43-49. doi: 10.1016/j.ejphar.2016.11.056. Epub 2016 Dec 1.

PMID:
27916555
5.

The drug candidate, ADX71441, is a novel, potent and selective positive allosteric modulator of the GABAB receptor with a potential for treatment of anxiety, pain and spasticity.

Kalinichev M, Girard F, Haddouk H, Rouillier M, Riguet E, Royer-Urios I, Mutel V, Lütjens R, Poli S.

Neuropharmacology. 2017 Mar 1;114:34-47. doi: 10.1016/j.neuropharm.2016.11.016. Epub 2016 Nov 23.

PMID:
27889489
6.

Phasic and Tonic mGlu7 Receptor Activity Modulates the Thalamocortical Network.

Tassin V, Girard B, Chotte A, Fontanaud P, Rigault D, Kalinichev M, Perroy J, Acher F, Fagni L, Bertaso F.

Front Neural Circuits. 2016 Apr 25;10:31. doi: 10.3389/fncir.2016.00031. eCollection 2016.

7.

Negative allosteric modulation of the mGlu7 receptor reduces visceral hypersensitivity in a stress-sensitive rat strain.

Moloney RD, Golubeva AV, O'Connor RM, Kalinichev M, Dinan TG, Cryan JF.

Neurobiol Stress. 2015 Apr 4;2:28-33. doi: 10.1016/j.ynstr.2015.04.001. eCollection 2015.

8.

Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders.

Kalinichev M, Le Poul E, Boléa C, Girard F, Campo B, Fonsi M, Royer-Urios I, Browne SE, Uslaner JM, Davis MJ, Raber J, Duvoisin R, Bate ST, Reynolds IJ, Poli S, Celanire S.

J Pharmacol Exp Ther. 2014 Sep;350(3):495-505. doi: 10.1124/jpet.114.214437. Epub 2014 Jun 19.

9.

Reduction of excessive alcohol drinking by a novel GABAB receptor positive allosteric modulator ADX71441 in mice.

Hwa LS, Kalinichev M, Haddouk H, Poli S, Miczek KA.

Psychopharmacology (Berl). 2014 Jan;231(2):333-43. doi: 10.1007/s00213-013-3245-z. Epub 2013 Aug 22.

10.

ADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7: in vitro and in vivo characterization.

Kalinichev M, Rouillier M, Girard F, Royer-Urios I, Bournique B, Finn T, Charvin D, Campo B, Le Poul E, Mutel V, Poli S, Neale SA, Salt TE, Lütjens R.

J Pharmacol Exp Ther. 2013 Mar;344(3):624-36. doi: 10.1124/jpet.112.200915. Epub 2012 Dec 20. Erratum in: J Pharmacol Exp Ther. 2013 May;345(2):328.

PMID:
23257312
11.

Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression.

Campo B, Kalinichev M, Lambeng N, El Yacoubi M, Royer-Urios I, Schneider M, Legrand C, Parron D, Girard F, Bessif A, Poli S, Vaugeois JM, Le Poul E, Celanire S.

J Neurogenet. 2011 Dec;25(4):152-66. doi: 10.3109/01677063.2011.627485.

PMID:
22091727
12.

Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania.

Kalinichev M, Dawson LA.

Int J Neuropsychopharmacol. 2011 Sep;14(8):1051-67. doi: 10.1017/S1461145710001495. Epub 2011 Jan 6.

PMID:
21208504
13.

Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics.

Bradford AM, Savage KM, Jones DN, Kalinichev M.

Psychopharmacology (Berl). 2010 Oct;212(2):155-70. doi: 10.1007/s00213-010-1938-0. Epub 2010 Jul 31.

PMID:
20676613
14.

Glycine transporter 1 (GlyT1) inhibitors exhibit anticonvulsant properties in the rat maximal electroshock threshold (MEST) test.

Kalinichev M, Starr KR, Teague S, Bradford AM, Porter RA, Herdon HJ.

Brain Res. 2010 May 17;1331:105-13. doi: 10.1016/j.brainres.2010.03.032. Epub 2010 Mar 18.

PMID:
20303337
15.

Potentiation of the anticonvulsant efficacy of sodium channel inhibitors by an NK1-receptor antagonist in the rat.

Kalinichev M, Bradford A, Bison S, Lucas A, Sartori I, Garbati N, Andreetta F, Bate S, Austin NE, Jones DN, Read KD, Alvaro G, Large CH.

Epilepsia. 2010 Aug;51(8):1543-51. doi: 10.1111/j.1528-1167.2009.02482.x. Epub 2010 Jan 7.

16.

Models of aspects of schizophrenia: behavioral sensitization induced by subchronic phencyclidine administration.

Kalinichev M, Bate ST, Jones DN.

Curr Protoc Pharmacol. 2009 Jun;Chapter 5:Unit 5.54. doi: 10.1002/0471141755.ph0554s45.

PMID:
22294400
17.

The relationship between sodium channel inhibition and anticonvulsant activity in a model of generalised seizure in the rat.

Large CH, Kalinichev M, Lucas A, Carignani C, Bradford A, Garbati N, Sartori I, Austin NE, Ruffo A, Jones DN, Alvaro G, Read KD.

Epilepsy Res. 2009 Jul;85(1):96-106. doi: 10.1016/j.eplepsyres.2009.02.018. Epub 2009 Mar 28.

PMID:
19329281
18.

Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine.

Davoodi N, Kalinichev M, Korneev SA, Clifton PG.

Psychopharmacology (Berl). 2009 May;203(4):693-702. doi: 10.1007/s00213-008-1415-1. Epub 2008 Dec 4.

PMID:
19052729
19.

Comparative effects of olanzapine and ziprasidone on hypophagia induced by enhanced histamine neurotransmission in the rat.

Davoodi N, Kalinichev M, Clifton PG.

Behav Pharmacol. 2008 Mar;19(2):121-8. doi: 10.1097/FBP.0b013e3282f62c66.

PMID:
18332676
20.

Locomotor reactivity to a novel environment and sensitivity to MK-801 in five strains of mice.

Kalinichev M, Bate ST, Coggon SA, Jones DN.

Behav Pharmacol. 2008 Feb;19(1):71-5. doi: 10.1097/FBP.0b013e3282f3cf48.

PMID:
18195596

Supplemental Content

Loading ...
Support Center